News Search Results
Sep 26, 2024, 09:00 ET ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
no console. It really saves space in the O.R. and is also quite efficient," says Dr. Sonia H. Yoo, Ophthalmology Professor of Ophthalmology, Cataract, Cornea and Lasik, Bascom Palmer Eye Institute, in Miami, Florida, USA. The ZEISS
More news about: Carl Zeiss Meditec AG
Sep 26, 2024, 09:00 ET ZEISS reinvents lens extraction with the first hand-held ultrasound-free lens removal device, available in the U.S.
no console. It really saves space in the O.R. and is also quite efficient," says Dr. Sonia H. Yoo, Ophthalmology Professor of Ophthalmology, Cataract, Cornea and Lasik, Bascom Palmer Eye Institute, in Miami, Florida, USA. The ZEISS
More news about: Carl Zeiss Meditec AG
Sep 26, 2024, 09:00 ET 5WPR Named Agency of Record for Eyesafe
Additionally, 5W will work to enhance exposure for Eyesafe's esteemed Vision Health Advisory Board, which is composed of leading experts in ophthalmology, optometry, and related fields who advocate for better eye health practices and the adoption of safer screen technologies. The
More news about: 5W Public Relations
Sep 26, 2024, 08:15 ET Rovia Clinical Research Launches as Parent Company to East Coast Institute for Research, Universal Axon Clinical Research, and IMIC Inc. Clinical Research Center
data collection and comprehensive analysis. Rovia's capabilities range across therapeutic disciplines, quickly expanding in areas such as Ophthalmology, Metabolism, Cardiovascular, Podiatry, Endocrinology, Gastroenterology, CNS, Hepatology, Infectious Disease, and Urology. About Rovia Clinical
More news about: Rovia Clinical Research
Sep 26, 2024, 08:00 ET Sun Pharma Presents New Clinical Efficacy and Safety Data in Severe Dermatological Conditions at the 2024 European Academy of Dermatology and Venereology (EADV) Congress
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Sep 26, 2024, 00:15 ET Innovent Announces NMPA Acceptance of NDA for Picankibart (Anti-IL-23p19 Antibody) for Treating Moderate to Severe Plaque Psoriasis
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for picankibart injection, a recombinant anti-interleukin 23p19 subunit
More news about: Innovent Biologics
Sep 25, 2024, 09:45 ET One Call Appoints Bruce Broussard to Board of Directors
Prior to Humana, Broussard was the CEO of McKesson Specialty Health where he and his team partnered with oncology, rheumatology, gastroenterology, ophthalmology, and neurology specialty providers to improve the health of their patients and practices. "Bruce brings a wealth of healthcare knowledge
More news about: One Call
Sep 25, 2024, 01:05 ET Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
Sep 25, 2024, 01:05 ET Biocon Biologics Announces New Dermatology Data to Be Presented at EADV Congress 2024
and Japan. It has a pipeline of 12 biosimilar assets under development across diabetology, oncology, immunology, ophthalmology, and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental, social
More news about: Biocon Biologics Ltd.
Sep 23, 2024, 07:30 ET Priovant Therapeutics Announces Receipt of Fast Track Designation from FDA for Brepocitinib in Non-Anterior Non-Infectious Uveitis (NIU) & Start of Enrollment of Brepocitinib Phase 3 NIU Program
measurement of posterior segment inflammation in uveitis," said Dilraj Grewal, MD, FASRS, Associate Professor of Ophthalmology, Vitreoretinal Surgery and Uveitis at Duke University and Associate Director of the Duke Reading Center, a comprehensive
More news about: Priovant Therapeutics
Sep 23, 2024, 06:44 ET IMF Celebrates Sewa Pakhwada in Mumbai, 3500 Beneficiaries Avail Free Treatment in Mega Multispecialty Health Camp as Part of PM Modi's Birthday Celebrations in Maharashtra
As many as 200 renowned doctors from 16 medical specialties including Gynecology, Oncology, Ophthalmology, General Medicine, Diagnostic, Radiation Oncology, Pediatrics, Orthopedics, Internal medicine, Dermatology, Preventive Medicine, Homeopathic, Allopathic
More news about: Chandigarh University
Sep 23, 2024, 06:00 ET Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
PhD, Clinical Professor of Ophthalmology Weill Cornell Medical College, Houston Methodist Hospital; Clinical Professor of Ophthalmology, Blanton Eye Institute; Director of Research, Retina Consultants of Texas; Deputy Chair of Ophthalmology, Blanton Eye InstituteKodiak's
More news about: Kodiak Sciences Inc.
Sep 23, 2024, 06:00 ET IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
Ocular Oncology Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University. "The successful FDA Type C meeting provides darovasertib a potential registrational
More news about: IDEAYA Biosciences, Inc.
Sep 19, 2024, 10:00 ET Beacon Therapeutics Presents 36-Month Interim Results from Phase I/2 HORIZON Trial of AGTC-501 in Patients with XLRP
Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. Lead development candidate AGTC-501, is a gene therapy program currently being investigated for the treatment of XLRP, an inherited
More news about: Beacon Therapeutics
Sep 19, 2024, 05:31 ET TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide
ophthalmology, making it a standout partner among global mid-sized CROs. These focus areas enable TFS to address some of the most pressing health challenges
More news about: TFS
Sep 19, 2024, 05:26 ET TFS HealthScience Unveils Mission to Empower Partners and Enrich Lives Worldwide
ophthalmology, making it a standout partner among global mid-sized CROs. These focus areas enable TFS to address some of the most pressing health challenges
More news about: TFS
Sep 19, 2024, 05:02 ET Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA
an e-poster, and will be published on the company's website following the congress. Yoreh Barak, MD, Head of Retina at the Department of Ophthalmology at Rambam Medical Center and the study's Principal Investigator, stated, "The data reported today confirm the effectivity, ease of use and tolerability
More news about: Everads Therapy
Sep 19, 2024, 03:00 ET Ada Health and Santéclair extend partnership, providing AI-powered care navigation to members of more than 60 insurance plans in France
which Ada's AI can direct members and healthcare professionals. This includes primary care; specialists such as mental health, women's health, ophthalmology, and osteopathy; condition-specific treatment options, including specialists for endometriosis, depression, and lower-back pain; preventative services
More news about: Ada Health
Sep 18, 2024, 17:15 ET Amniotic Membrane Market to Grow by USD 2.7 Billion (2024-2028) with AI Impact Boosting Trends in Ophthalmic Surgery Use - Technavio Report
applications include ophthalmology, with a focus on eye conditions like corneal ulcers and pterygium excisions. The market also caters to non-healing chronic wounds, burn injuries, and pressure ulcers. Amniotic membranes are used as surgical grafts and biological bandages in ophthalmology surgeries, cosmetic
More news about: Technavio
Sep 18, 2024, 09:48 ET New Report: Private Equity-Affiliated Physician Practices Associated with Lower Medicare Expenditures, Fewer Inpatient Days, and Fewer Emergency Department Visits
well as the specialties of Cardiology, Dermatology, Emergency Medicine, Gastroenterology, Hematology/Medical Oncology, Nephrology, Neurosurgery, Ophthalmology, Orthopedic Surgery, Otolaryngology, Radiation Oncology, Urology, Vascular Medicine, and Women's Health. Media Contact:
More news about: American Independent Medical Practice Association
Sep 17, 2024, 20:00 ET Innovent Announces Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) Combined with Bevacizumab in Advanced Colorectal Cancer at the 2024 ESMO Congress
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that clinical data of IBI363 (first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein)
More news about: Innovent Biologics
Sep 17, 2024, 16:05 ET Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City
PhD, Clinical Professor of Ophthalmology Weill Cornell Medical College, Houston Methodist Hospital; Clinical Professor of Ophthalmology, Blanton Eye Institute; Director of Research, Retina Consultants of Texas; Deputy Chair of Ophthalmology, Blanton Eye Institute Investor
More news about: Kodiak Sciences Inc.
Sep 17, 2024, 06:50 ET Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector
segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; and gastrointestinal products. Its Specialty Generics
More news about: Mallinckrodt plc
Sep 16, 2024, 11:00 ET ABMS Announces Class of 2024-2025 Visiting Scholars
Relationship of ABOG Certification with Early Career Patient Outcomes in Obstetrics and GynecologyAmerican Board of Ophthalmology Julius Oatts, MD – University of California, San Francisco
More news about: American Board of Medical Specialties
Sep 16, 2024, 08:47 ET Piramal Pharma's GHG Commitment Validated and Approved by SBTi
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd